Cyclosporin exposure correlates with 1 year graft function and histological damage in renal transplanted patients

Nephrology Dialysis Transplantation

Volumn 19, Issue 8, 2004, Pages 2107-2112

  di Paolo, Salvatore ^a   Teutonico, Annalisa ^a   Stallone, Giovanni ^a   Infante, Barbara ^a   Schena, Antonio ^a   Grandaliano, Giuseppe ^a   Battaglia, Michele ^a   Ditonno, Pasquale ^a   Schena F , Paolo ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

C2 monitoring; Chronic allograft nephropathy; Cyclosporin; Graft function; Kidney transplantation

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CREATININE; CYCLOSPORIN; CYCLOSPORIN A; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACCURACY; ACUTE GRAFT REJECTION; ADOLESCENT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY BIOPSY; KIDNEY INJURY; KIDNEY INTERSTITIUM; KIDNEY TRANSPLANTATION; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MONITORING, IMMUNOLOGIC; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES;

EID: 4344577015     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfh344     Document Type: Article

References (20)

1. Keown P, Landsberg D, Halloran P et al., Canadian Neoral Renal Transplantation Study Group. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation 1997; 62: 1744 1752
2. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993; 54: 205-218
3. Levy GA. C2 monitoring strategy for optimising cyclosporine immunosuppression from the Neoral formulation. Biodrugs 2001; 15: 279-290
4. Batiuk TD, Kung L, Halloran PF. Evidence that calcineurin is rate-limiting for primary human lymphocyte activation. J Clin Invest 1997; 100: 1894-1901
5. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation 1999; 68: 1356-1361
6. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999; 68: 55-62
7. International Neoral Renal Transplantation Study Group. Cyclosporine microemulsion (Neoral®) absorption profiling and sparse-sample predictors during the first 3 months after renal transplantation. Am J Transplant 2002; 2: 148-156
8. International Neoral Renal Transplantation Study Group. Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis. Am J Transplant 2002; 2: 157-166
9. Pescovitz MD, Barbeito R, for the Simulect US01 Study Group. Two-hour post dose cyclosporin level is a better predictor than trough level of acute rejection of renal allografts. Clin Transplant 2002; 16: 378-382
10. Clase CM, Mahalati K, Kiberd BA et al. Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling. Am J Transplant 2002; 2: 789-795
11. Hariharan S, McBride MA, Cherikh WS, Tolleris CB, Bresnahan BA, Johnson CP. Post-transplant renal function in the first year predicts long-term kidney transplant survival. Kidney Int 2002; 62: 311-318
12. Yilmaz S, Tomlanovich S, Mathew T et al. Protocol core needle biopsy and histologic chronic allograft damage index (CADI) as surrogate end point for long-term graft survival in multicenter studies. J Am Soc Nephrol 2003; 14: 773-779
13. Di Paolo S, Stallone G, Schena A, Infante B, Gesualdo L, Schena FP. Hypertension is an independent predictor of delayed graft function and worse renal function only in kidneys with chronic pathological lesions. Transplantation 2002; 73: 623-627
14. 2 monitoring of cyclosporine microemulsion. Transplantation 2003; 76: 903-908
15. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713-723
16. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit 2002; 24: 479-486
17. Perico N, Ruggenenti P, Gotti E et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MYSS trial. Kidney Int 2004; 65: 1084-1090
18. Mahalati K, Belitsky P, West K et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol 2001; 12: 828-833
19. Kahan BD, Welsh M, Schoenberg L et al. Variable oral absorption of cyclosporine. A biopharmaceutical risk factor for chronic renal allograft rejection. Transplantation 1996; 62: 599-606
20. Keown PA, Niese D, for the International Sandimmun Neoral Study Group. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group. Kidney Int 1998; 54: 938-944